



ANDA 202718

ANDA APPROVAL

Teva Pharmaceuticals USA
425 Privet Road
Horsham, PA 19044

Attention: Rich Leone
Senior Director, Regulatory Affairs, U.S. Generics

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated December 30, 2010, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Morphine Sulfate Extended-release Capsules USP, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg and 100 mg.

Reference is also made to the Complete Response letter issued by this office on January 13, 2014 and to your amendments dated February 19, April 15, May 16, November 13, November 20, and December 2, 2014.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Morphine Sulfate Extended-release Capsules USP, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg and 100 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug product (RLD), Morphine Sulfate Extended-release Capsules USP, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg and 100 mg, of Watson Labs, Inc.

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application. The "interim" dissolution specifications are as follows:

Dissolution testing should be conducted in:

Apparatus:	USP Apparatus I (Basket)
Speed:	100 rpm
Medium:	Acid Stage: 0.1 N HCl for 1 hr Buffer Stage: Phosphate Buffer pH 7.5 for NLT 8 hrs
Volume:	500 mL
Temperature:	37°C ± 0.5°C
Specifications:	Acid Stage: 1 hr NMT (b)(4)% Buffer Stage: 4 hrs (b)(4)% 6 hrs (b)(4)% 9 hrs NLT (b)(4)%

The “interim” dissolution test(s) and tolerances should be finalized by submitting dissolution data for the first three production size batches. Data should be submitted as a Special Supplement – Changes Being Effected when there are no revisions to the “interim” specifications or when the final specifications are tighter than the “interim” specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the FDCA authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS) if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)]. In accordance with section 505-1(i) of FDCA, an ANDA is required to have a REMS if the applicable listed drug has an approved REMS.

The details of the REMS requirements were outlined in our REMS notification letter dated April 19, 2011. In that letter, you were also notified that in the interest of public health and to minimize the burden on the healthcare delivery system of having multiple unique REMS programs, a single, shared system should be used to implement the REMS for applicants of Extended-Release and Long-Acting (ER/LA) opioid analgesics.

Your proposed REMS, submitted December 2, 2014, and appended to this letter, is approved. The REMS consists of a Medication Guide, elements to assure safe use, and a timetable for submission of assessments.

This REMS uses a single, shared system for the elements to assure safe use and the REMS assessments. This single, shared system is known as the ER/LA Opioid Analgesics REMS. This single, shared system, known as the ER/LA Opioid Analgesics REMS Program, currently includes the products listed on the FDA REMS website available at <http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM348818.pdf> Other products may be added in the future if additional NDAs or ANDAs are approved.

Under section 505-1(g)(2)(C), FDA can require the submission of a REMS assessment if FDA determines that an assessment is needed to evaluate whether the approved strategy should be

modified to ensure the benefits outweigh the risks of the drug or to minimize burden on the healthcare system of complying with the REMS. The details for what should be included in any joint assessments completed under the ER/LA Opioid Analgesics REMS are listed in Appendix 1.

We remind you that section 505-1(f)(8) of the Act prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify the submission containing a proposed modification of the REMS or any REMS assessments with the following wording in bold capital letters at the top of the first page of the submission:

**ANDA 202718
REMS ASSESSMENT**

**NEW SUPPLEMENT FOR ANDA 202718
PROPOSED REMS MODIFICATION**

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self

identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

**William P.
Rickman -S**

for Carol A. Holquist, RPh
Acting Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

Digitally signed by William P. Rickman -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People,
0,9.2342.19200300.100.1.1=1300043242,
cn=William P. Rickman -S
Date: 2014.12.29 14:34:16 -05'00'

Attachments: APPENDIX 1
REMS